Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a disease characterized by the progressive accumulation of monoclonal CD5 þ , CD19 þ and CD23 þ B-cells in the blood, lymphoid tissues and marrow. Because nearly all CLL/SLL cells in the blood are in G 0 /G 1 phase of the cell cycle, it has been assumed that CLL/SLL was due to the slow accumulation of incompetent lymphocytes that cannot normally undergo apoptosis. However, isotopic labeling of the CLL/SLL cells in vivo revealed that CLL/SLL is rather a dynamic process with high rates of leukemia cell turnover, often at levels exceeding 0.1-1.75% of the entire CLL/SLL clone per day. 1 Given that a CLL/SLL clone contains between 10 12 and 10 14 cells, this high rate of turnover implies that some patients might generate B10 9 to 10 12 CLL/SLL cells each day. This has led to speculation that there must be at least two compartments for CLL/SLL, one in which quiescent, leukemia B cells might accumulate, such as the blood, and another comprised of proliferating B cells that might be housed in the marrow and/or secondary lymphoid tissues of patients with this disease. 2 Increasingly, the proliferating compartment is posted to exist within pseudofollicles, which can be found in secondary lymphoid tissues of patients with CLL/SLL. Such pseudofollicles contain stromal cells, T cells and B cells, which express markers Letters to the Editor associated with activation and proliferation, for example, Ki-67, and the anti-apoptotic protein survivin, a member of the inhibitor of apoptosis family considered to have a role in promoting leukemia cell survival. 3 Immunohistochemical investigations of these pseudofollicles have revealed many properties in common with reactive B-cell follicles, suggesting that they may be centers of antigen-driven proliferation. 4 Because these pseudofollicles are assumed to contain proliferating leukemia B cells, increasingly they have been designated as proliferation centers for CLL/SLL.
Although the proliferating B cells within such pseudofollicles have been assumed to be leukemia B cells, there have been no studies that have critically assessed for a clonal relationship between leukemia B cells in the blood and proliferating B cells in the pseudofollicle. Conceivably, pseudofollicles could represent aberrant secondary lymphoid follicles that have a distorted architecture because of the diffuse infiltration of the lymph node (LN) by leukemia B cells. In this case, the proliferating B cells of such pseudofollicles would lack a clonal relationship with the leukemia B cells, but instead represent residual normal, non-leukemia B cells that are engaged in an immune response to antigen(s).
Bonato et al. 5 showed a good correlation in terms of heavy and light chain expression between LN sections and peripheral blood (PB). Nevertheless, these data do not prove the proliferation of the leukemia cells in the pseudofollicles, as accumulating leukemia cells in the LNs would lead to the same result. Isobe et al. 6 reported that in one of the two CLL/SLL patients analyzed, dissected pseudofollicle cells showed intraclonal diversity, similar to the leukemia cells in the PB. However, these investigators did not examine for markers of cellular proliferation, making it difficult to conclude that the examined cells were undergoing replication within these pseudofollicles. Because there have not been molecular studies on such cells, it is still uncertain whether the proliferating cells within such pseudofollicles have a clonal relationship with the leukemia cell clone. Because of this, we isolated proliferating cells from the pseudofollicles of patients with CLL/SLL for molecular analyses and comparison with the leukemia cells in the PB.
To detemine whether the proliferating cells in each pseudofollicle were comprised of B cells, T cells or both, we performed immunofluorescent double labeling using monoclonal antibodies specific for Ki67, a nuclear antigen expressed exclusively in proliferating cells, 7 together with monoclonal antibodies specific for CD79-a or CD3. LN biopsies were evaluated from seven patients with CLL/SLL, undergoing evaluation for Richter's transformation (which was not present). In all of these cases, the LN architecture was ablated by a diffuse infiltration of welldifferentiated lymphocytes and contained pale pseudofollicles of cells with increased reactivity with the anti-Ki67 monoclonal antibody. In the LN sections from patient seven, we observed some germinal centers (GCs) in addition to pseudofollicles. The CD79-a/Ki67-double-positive cells in the pseudofollicles (Figures 1a and b ) illustrate that these pseudofollicles contain proliferating B cells. Moreover, our data show that the T cells present in the pseudofollicles were not actively proliferating (Figures 1c and d) . We also examined the GCs found in the LN ; (e) GC of patient 7, double-labeled for Ki67 (red) and CD79-a (green) and stained using 4 0 ,6-diamidino-2-phenylindol to visualize cell nuclei (blue); (f) increased magnification of the image in e, showing that the Ki67 þ cells (red) also weakly express CD79-a (green); (g) GC of patient 7, double-labeled for Ki67 (red) and CD3 (green) and stained using 4 0 ,6-diamidino-2-phenylindol to visualize cell nuclei (blue); (h) increased magnification of the image in g, showing that the Ki67 þ cells (red) are CD3
À .
Letters to the Editor from patient 7. As was shown in animals, 8 CD79-a is more strongly expressed in the follicular mantle zone than in the GC. Nevertheless, the Ki67 þ cells in the GC weakly express CD79-a but do not express CD3 (Figures 1e and h ).
We performed laser capture microdissection to isolate pseudofollicle sections (containing both Ki67 þ and Ki67 À cells) from these LN biopsies and then isolated the Ki67 þ cells from selected pseudofollicles (Figure 2 ). The immunoglobulin heavy chain variable region (IGHV) genes and immunoglobulin (Ig) rearrangements of isolated B cells were compared with the IGHV and Ig rearrangements of leukemia B cells in the blood of the same patient. These studies allowed us to assess the clonal relationship between proliferating B cells in the pseudofollicles and the generally quiescent, non-proliferating leukemia B cells found in the blood. We examined the isolated genomic DNA for clonal rearrangements by PCR using the IGH Gene Clonality Assay (InVivoScribe Technologies, Carlsbad, CA, USA). The DNA was amplified using consensus primers specific for framework (FR)1, FR2, FR3 and J H regions of the immunoglobulin heavy chain gene. One of the primers in the primer pairs was fluorescent dye labeled and analysis of the amplified products was performed by capillary electrophoresis using an automated DNA sequencer (ABIPrism 3100, Applied Biosystems, Foster City, CA, USA). For the DNA sequencing of the CLL/SLL cells in the PB, six IGHV family specific-primers annealing to sequences in the leader region and a consensus primer for the heavy chain joining region were used. For the LN samples and for patient 4, IGHV family-specific primers annealing to sequences in the FR1 region were used. Clonal PCR products were purified with the Qiaquick PCR Purification Kit (Qiagen, Venlo, The Netherlands), and both strands were sequenced by fluorescence dideoxy chain termination (BigDye Terminator v3.1 Cycle Sequencing Kit, Applied Biosystems), using an ABI 3130 Genetic Analyser (Applied Biosystems).
To control for our studies on CLL/SLL samples, we used laser capture microdissection to isolate B cells from the lymphoid tissues of healthy individuals. Our analyses on the IGHV rearrangements from blood B cells of a healthy volunteer, on 168, 20 or 10 GCs of a benign reactive LN, or on 20 GCs from a non-neoplastic tonsil revealed a Gaussian distribution of the amplicon lengths. This contrasted with the analysis of the IGHV rearrangements found in a B-cell lymphoma cell line (Farage), which was monoclonal. It was also shown, using 2000 Ki67 þ cells isolated from the GCs of a benign reactive LN, that low amounts of cells do not generate pseudomonoclonal bands. These controls ensure that the bands detected in the patient samples truly reflect the clonality of the corresponding sample.
Immunoglobulin heavy chain clonality studies of the DNA extracted from the CLL/SLL patient's pseudofollicle sections, containing both Ki67 þ and Ki67 À cells, and from the Ki67 þ cells isolated from these pseudofollicles reveal one, and in case of patient 7, two dominant or, more probably, biallelic clonal B-cell populations. These clonal B-cell populations have the same fragment length as the ones that are detected in the PB of the corresponding patients. In addition, in two of the LN samples (patients 1 and 2) sequence data could be obtained for each patient from the DNA of 2000 Ki67 þ cells isolated from a pseudofollicle. For both samples, isolated IGHV sequence was the same as that found for the CLL/SLL cells in the blood (GenBank accession numbers: see Table 1 ). The sequences were checked on the single nucleotide level. Clonality and V H rearrangements are shown in Table 1 . Immunoglobulin heavy chain joining region (IGHJ), immunoglobulin heavy chain diversity region (IGHD) and the amino acid sequence of the junction were also identical in the corresponding PB and in the LN samples of patients 1 and 2 (patient 1: immunoglobulin heavy chain joining region: 6 n 02, immunoglobulin heavy chain diversity region: 3-3 n 01 and amino acid sequence CARGTP-NYDFWSGYSVS; patient 2: immunoglobulin heavy-chain joining region: 6 n 02, immunoglobulin heavy chain diversity region: 6-13 n 01 and amino acid sequence CARDGNAMDVW). Abbreviations: FR, framework; GC, germinal center; M, mutated; ND, not detected (GCs were detected only in patient 7); PB, peripheral blood; PC, proliferation center; UM, unmutated.
a No result or result below threshold (peak height 100).
In two patients (patient 3 and patient 5), sequencing analysis revealed two immunoglobulin heavy chain variable region rearrangements in leukemia cells from the blood, whereas clonality assessment showed only one rearrangement. According to the IGH Gene Clonality Assay (InVivoScribe Technologies) package insert, this clonality assay is not necessarily able to detect all clonalities which explains the discrepancy between the sequencing results and the clonality results.
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For the other five samples (patients 3-7), we could not obtain adequate sequence data from the DNA isolated from 2000 Ki67 þ pseudofollicular B cells to make such comparisons. Nevertheless, in each of these cases, we found the length of the Ig heavy chain variable diversity joining (VDJ) junction matched that of the Ig heavy chain expressed by the leukemia cells isolated from the PB, supporting the conclusion that these cells were clonally related.
In addition, 2000 Ki67 À cells from 40 different pseudofollicles from patient 2 were pooled to elucidate the composition of the Figure 4 IGHV gene clonality assessment, data generated using IGHV-FR3 primers: (a) the analyses on the blood leukemia cells of patient 7 showed two clonal rearrangements; (b) the analyses on the pseudofollicular pool of patient 7, containing both proliferating and non-proliferating cells, also showed both clonal rearrangements; (c) analyzing 2000 Ki67 þ cells from the pseudofollicles of patient 7 revealed that the proliferating cells in the pseudofollicles were composed of cells with the same rearrangements as that of the CLL/SLL cells found in the blood, along with a basal presence of other rearrangements; (d) both clonal rearrangements also are detected in the analyses on the GC pool, containing both proliferating and non-proliferating cells, along with other polyclonal rearrangements; (e) analyzing 2000 Ki67 þ cells from the GCs of patient 7 showed that the proliferating cells in the GCs are polyclonal and do not contain the two IGHV rearrangements found in blood leukemia cells.
non-proliferative fraction in the pseudofollicles. As shown in Figure 3, (Figure 4a ). These two rearrangements were both detected in the pseudofollicular pool (containing both Ki67 þ and Ki67 À cells) isolated from this patient's LN (Figure 4b) . Furthermore, clonality assessment revealed that the Ki67 þ , proliferating cells in the pseudofollicles (Figure 4c ) are cells with the same rearrangements as the CLL/SLL cells in the blood, along with a basal presence of other, polyclonal, rearrangements. This is the only patient in whom other IGHV rearrangements than that found in blood leukemia cells were observed in the Ki67 þ fraction within the pseudofollicles (compare Figures 3a and 4c) . The two clonal rearrangements found in the PB are also present in the GC pool (containing both Ki67 þ and Ki67 À cells; Figure 4d ), but the Ki67 þ , proliferating cells in these GCs are polyclonal and do not contain the two CLL/ SLL rearrangements found in the PB (Figure 4e ). This means that the CLL/SLL cells do not proliferate in the GCs but may accumulate there as a non-proliferating fraction. In this patient, normal B-cells are proliferating in the GCs and to a lesser extent in the pseudofollicles.
In conclusion, our data provide formal proof that the proliferating B cells within pseudofollicles are clonally related to the quiescent leukemia cells found in the blood of patients with CLL/SLL. Because these pseudofollicular B cells have a relatively high proportion of Ki-67-positive cells compared with the leukemia B cells in the blood, these findings support the notion that these pseudofollicles are the major sites for leukemia cell proliferation. This finding is of critical importance when considering the biology of CLL/SLL. It confirms that targeting the actively proliferating cells in the LN, that maintain the CLL/SLL clone, by a cell-cycle-active agent can indeed be considered as an important therapeutic approach. In addition, we speculate that disrupting the microenvironment of these pseudofollicles might interfere with factors that accommodate CLL/SLL cell proliferation, thereby potentially providing novel ways in which to inhibit the progression of this disease.
